Prevalence of Histoplasmosis in HIV + Patients with a Rapid Diagnostic Test in West Indies (EDIRAPHIS)
Histoplasmosis in the Guiana Shield and the French West Indies: Evaluating Prevalence in HIV + Patients with a Rapid Diagnostic Test Using an ELISA Capture Method for the Detection of Histoplasma Antigens in Blood and Urine.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Guadeloupe
-
Pointe-à-Pitre, Guadeloupe, France, 97159
- Pointe-à-Pitre University Hospital
-
-
Guyane
-
Cayenne, Guyane, France, 97306
- Cayenne General Hospital
-
Saint-Laurent-du-Maroni, Guyane, France, 97320
- Western French Guiana Hospital
-
-
Martinique
-
Fort-de-France, Martinique, France, 97261
- Fort-de-France University Hospital
-
-
-
-
-
Paramaribo, Suriname
- 's Lands Hospital
-
Paramaribo, Suriname
- Academisch Ziekenhuis Paramaribo Hospital
-
Paramaribo, Suriname
- Diakonessenhuis Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult (aged 18 or over).
- Patient seen while hospitalized or in outpatient awaiting hospitalization.
- HIV1 or HIV2 infection confirmed by techniques validated in France and in Suriname, either before the episode considered, or discovered concomitantly.
- Patient presenting at least one of the three followings items: an alteration of their general condition (with a grade 1 according to the WHO Performance Status scale) and/or a fever and/or symptoms suggestive of an infectious syndrome.
- Medical prescription for the collection of blood and urine specimens to test for an infectious agent within 7 days following admission to the hospital.
- Written consent to participate in the study obtained.
Exclusion Criteria:
- Refusal to participate in the study.
- Patient in a critical condition that doesn't allow physicians to get an informed consent without a legal representative to represent him and sign a consent form for the patient participation in the study.
- Ongoing antifungal treatment or antifungal treatment stopped during the month preceding the inclusion date (topic antifungal therapy not considered at this point).
- Patient in detention at the time of admission to the hospital.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of HIV-infected patients hospitalized or in outpatient awaiting hospitalization for a suspicion of infectious syndrome whose serum and/or urinary antigen detection tests are positive for Histoplasma capsulatum var. capsulatum.
Time Frame: At the time of inclusion (baseline)
|
At the time of inclusion (baseline)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Sensitivity of the ELISA test on urine and blood specimens
Time Frame: At the time of inclusion (baseline)
|
At the time of inclusion (baseline)
|
|
Sensibility of the ELISA test on urine and blood specimens
Time Frame: At the time of inclusion (baseline)
|
At the time of inclusion (baseline)
|
|
Negative predictive value of the ELISA test on urine and blood specimens
Time Frame: At the time of inclusion (baseline)
|
At the time of inclusion (baseline)
|
|
Comparison of the distribution of Histoplasma antigen concentrations in urine and serum specimens according to severity of cases of histoplasmosis due to Histoplasma capsulatum var. capsulatum
Time Frame: At the time of inclusion (baseline)
|
At the time of inclusion (baseline)
|
|
Comparison of the socio-demographic, clinical, paraclinical and therapeutic characteristics according to severity of cases of histoplasmosis due to Histoplasma capsulatum var. capsulatum
Time Frame: 30 days or 90 days after inclusion
|
30 days or 90 days after inclusion
|
|
Comparison of the factors for environmental exposure to Histoplasma capsulatum var capsulatum between patients with a positive ELISA test and/or fungal culture for histoplasmosis and those who tested negative for histoplasmosis
Time Frame: At the time of inclusion
|
At the time of inclusion
|
|
Frequency of histoplasmosis compared to the other main diagnoses according to three sets of comparisons: positive ELISA test and positive fungal culture; positive ELISA test and negative fungal culture; negative ELISA test and positive fungal culture
Time Frame: 90 days after inclusion
|
90 days after inclusion
|
|
Comparison of the socio-demographic, clinical, paraclinical, therapeutic and survival outcome characteristics of cases of histoplasmosis compared to those who tested negative for histoplasmosis
Time Frame: 90 days after inclusion
|
90 days after inclusion
|
|
Identify the prognostic factors for short-term unfavourable progression of cases of histoplasmosis due to Histoplasma capsulatum var. capsulatum confirmed by ELISA test and/or by fungal culture
Time Frame: 30 days and 90 days after inclusion
|
30 days and 90 days after inclusion
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Mathieu NACHER, MD, PhD, CIE 802 Inserm / DGOS
- Study Chair: Stephen G VREDEN, MD, PhD, Foundation for Scientific Research Suriname (SWOS)
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ANRS 12260 EDIRAPHIS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.